• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    12/12/23 4:31:09 PM ET
    $FATE
    $FWBI
    $GRCL
    $HEPA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FATE alert in real time by email

    Gainers

    • Reshape Lifesciences (NASDAQ:RSLS) shares rose 58.2% to $0.4 during Tuesday's after-market session. The company's market cap stands at $5.2 million.
    • NightHawk Biosciences (AMEX:NHWK) shares moved upwards by 12.9% to $0.35. The company's market cap stands at $9.1 million.
    • Minerva Surgical (NASDAQ:UTRS) shares rose 9.99% to $2.42. The company's market cap stands at $21.4 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 9.5% to $0.22. The market value of their outstanding shares is at $2.6 million.
    • Inhibikase Therapeutics (NASDAQ:IKT) stock moved upwards by 8.33% to $1.3. The company's market cap stands at $8.0 million.
    • Senti Biosciences (NASDAQ:SNTI) stock rose 8.31% to $0.38. The market value of their outstanding shares is at $16.8 million.

    Losers

    • LumiraDx (NASDAQ:LMDX) stock decreased by 7.7% to $0.11 during Tuesday's after-market session. The company's market cap stands at $36.6 million.
    • Fate Therapeutics (NASDAQ:FATE) shares declined by 6.67% to $2.24. The company's market cap stands at $220.8 million.
    • Sera Prognostics (NASDAQ:SERA) shares declined by 5.51% to $4.46. The market value of their outstanding shares is at $139.7 million.
    • Gracell Biotechnologies (NASDAQ:GRCL) shares fell 5.0% to $5.14. The market value of their outstanding shares is at $493.0 million.
    • First Wave BioPharma (NASDAQ:FWBI) stock fell 4.84% to $0.29. The company's market cap stands at $3.9 million.
    • Hepion Pharmaceuticals (NASDAQ:HEPA) stock decreased by 4.82% to $3.76. The company's market cap stands at $16.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $FATE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FATE
    $FWBI
    $GRCL
    $HEPA

    CompanyDatePrice TargetRatingAnalyst
    Inhibikase Therapeutics Inc.
    $IKT
    3/4/2026$4.00Buy
    Ladenburg Thalmann
    Inhibikase Therapeutics Inc.
    $IKT
    1/21/2026$6.00Buy
    BofA Securities
    Inhibikase Therapeutics Inc.
    $IKT
    12/26/2025$8.00Buy
    H.C. Wainwright
    Sera Prognostics Inc.
    $SERA
    12/15/2025$5.00Buy
    Jefferies
    Inhibikase Therapeutics Inc.
    $IKT
    12/11/2025$4.00Overweight
    Cantor Fitzgerald
    Fate Therapeutics Inc.
    $FATE
    10/31/2025$5.00Neutral → Buy
    H.C. Wainwright
    Fate Therapeutics Inc.
    $FATE
    10/27/2025$7.00Neutral → Outperform
    Wedbush
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Inhibikase Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $4.00

    3/4/26 8:37:45 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Inhibikase Therapeutics with a new price target

    BofA Securities initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $6.00

    1/21/26 8:55:17 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Inhibikase Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $8.00

    12/26/25 8:50:26 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sands Capital Life Sciences Pulse Fund Ii, L.P. bought $2,999,999 worth of shares (2,068,965 units at $1.45) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    11/24/25 3:47:02 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/26/24 9:00:15 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bellini Roberto bought $2,000,200 worth of shares (1,460,000 units at $1.37) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    10/23/24 7:53:27 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Stetz Gary S.

    3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/18/26 5:25:00 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Hepion Pharmaceuticals Inc.

    3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/18/26 5:22:38 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Hepion Pharmaceuticals Inc.

    3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/18/26 5:20:55 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $FATE
    $FWBI
    $GRCL
    $HEPA
    SEC Filings

    View All

    Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

    WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), announced today that the first patient has been enrolled in the Company's pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). "Enrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate th

    4/7/26 8:00:00 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the "Inducement Plan"), effective as of March 31, 2026 (the "Effective Date"). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The

    4/3/26 2:01:00 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering in

    4/2/26 4:05:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)

    4/7/26 8:09:02 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Other Events

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    4/1/26 4:31:42 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Senti Biosciences Inc.

    SCHEDULE 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    3/31/26 5:58:16 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    11/14/24 7:50:18 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

    SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of new peer-reviewed research in Cell Systems demonstrating its systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in both T cells and natural killer (NK) cells. The study demonstrates how Logic-Gated receptor designs can significantly improve the efficacy, precision, and safety of cell therapies by enabling immune cells to selectively eliminate tumor cells while sparing hea

    4/1/26 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENT

    3/27/26 8:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

    SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California. The presentations will include data from the ongoing Phase I clinical trial of SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing he

    3/23/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    $FWBI
    $GRCL
    $HEPA
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

    SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experience in the life sciences industry, including over 10 years serving as CFO across innovative life science companies, with deep domain expertise in autoimmune diseases, including lupus. "We are excited to wel

    10/14/25 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care